Europe’s Cannabis Market Faces Hurdles for American Expansion
AI-generated context summary requested by a Free News Reader user. Sourced via Gemini from publicly available information — no paywalled content was accessed.
You hit a paywall. Here’s the context on this topic based on publicly available information. We did not access any paywalled content. View original article.
Europe's Cannabis Market Faces Hurdles for American Expansion
- The European medical cannabis market is projected to grow significantly, from approximately $3.06 billion in 2025 to over $13.1 billion by 2034.
- Kojo Koram, author of "The Next Fix: The Winners and Losers in the Future of Drugs," highlights concerns about overhyping cannabis benefits while downplaying risks as the industry expands globally.
Full Summary — powered by AI
The European cannabis market is experiencing rapid growth, particularly in the medical sector, with projections indicating a rise from roughly $3.06 billion in 2025 to more than $13.1 billion by 2034. This expansion is driven by evolving regulatory frameworks and increasing patient access across the continent. Countries like Germany and the UK are leading this growth, with Germany dominating as Europe’s largest medical cannabis market.
Despite this promising outlook, American cannabis companies looking to enter the European market face significant challenges. A major hurdle is the stringent EU-GMP (European Union Good Manufacturing Practice) certification required for cannabis products to be sold in European pharmacies. Many producers, while strong in cultivation, underestimate the differences between the European pharmaceutical framework and other cannabis markets. This means products commercially viable elsewhere may need substantial work to meet European medical standards.
The US cannabis market, valued at approximately $36.82 billion in 2025, operates under a patchwork of state-level legalizations, with cannabis remaining federally illegal. This creates complexities, including a lack of interstate commerce and the inability for businesses to deduct standard expenses due to federal tax code 280E. In contrast, European cannabis companies operating vertically are not subject to these tax disadvantages. Furthermore, concerns exist about the potential for American expansion to oversell the benefits of cannabis while minimizing its risks, according to Kojo Koram, a legal scholar and author.